Prokocimer M, Modan M, Rusoshansky S, Bairey O, Shaklai M
Hematology Division, Beilinson Medical Center, Petah Tiqva, Israel.
Anticancer Res. 1989 Jul-Aug;9(4):1233-5.
ProMACE CytaBOM, a polychemotherapy regimen consisting of cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate and prednisone was administered on an outpatient basis to six consecutive patients with diffuse large cell lymphoma. All achieved a complete remission (CR). Two have relapsed. Actuarial analysis predicts 66.7% survival and 62.5% probability of remaining in remission at 40 months post diagnosis. The side effects of ProMACE CytoBOM were tolerable and included mainly vincristine induced peripheral neuropathy, infections and mucositis. Our results are consistent with the SWOG results, reported only recently, using the same combination chemotherapy regimen in patient with intermediate and high-grade non-Hodgkin's lymphomas. We conclude that ProMACE CytaBOM represents a highly effective and easy-to-administer regimen in patients with large cell lymphoma.
ProMACE CytaBOM方案，一种由环磷酰胺、阿霉素、依托泊苷、阿糖胞苷、博来霉素、长春新碱、甲氨蝶呤和泼尼松组成的多药化疗方案，在门诊对6例连续的弥漫性大细胞淋巴瘤患者进行了治疗。所有患者均实现完全缓解（CR）。2例复发。精算分析预测诊断后40个月的生存率为66.7%，缓解持续概率为62.5%。ProMACE CytaBOM方案的副作用是可耐受的，主要包括长春新碱引起的周围神经病变、感染和粘膜炎。我们的结果与SWOG最近报告的结果一致，后者在中、高度非霍奇金淋巴瘤患者中使用了相同的联合化疗方案。我们得出结论，ProMACE CytaBOM方案对大细胞淋巴瘤患者来说是一种高效且易于给药的方案。
